1/4/2023 7:43:52 AM
Aravive Completes Enrollment In Phase 3 AXLerate-OC Trial For Platinum-Resistant Ovarian Cancer
11/29/2022 7:15:36 AM
Aravive: FDA Grants Fast Track Designation To Batiraxcept For Patients With CcRCC
11/16/2022 7:05:04 AM
Aravive Regains Compliance With Nasdaq Minimum Bid Price Requirement
6/24/2021 7:24:20 AM
Aravive Says Positive Initial Results From Phase 1b Study Of AVB-500 With Cabozantinib In Clear Cell Renal Carcinoma
3/8/2021 7:11:18 AM
Aravive Doses First Patient Dosed In Phase 1b/2 Clinical Trial Of AVB-500 In Clear Cell Renal Cell Carcinoma
5/10/2019 6:50:14 AM
Wedbush Is Increasing Aravive, Inc. (ARAV) FY20 Estimate To -1.89 From -2.49
5/10/2019 6:49:58 AM
Wedbush Is Increasing Aravive, Inc. (ARAV) Q4 20 Estimate To -0.43 From -0.56
5/10/2019 6:49:42 AM
Wedbush Is Raising Aravive, Inc. (ARAV) Q3 20 Estimate To -0.52 From -0.69
5/10/2019 6:49:28 AM
Wedbush Is Raising Aravive, Inc. (ARAV) Q2 20 Estimate To -0.48 From -0.64
5/10/2019 6:49:14 AM
Wedbush Is Increasing Aravive, Inc. (ARAV) Q1 20 Estimate To -0.45 From -0.60
5/10/2019 6:48:54 AM
Wedbush Is Increasing Aravive, Inc. (ARAV) FY19 Estimate To -1.91 From -2.87
5/10/2019 6:48:41 AM
Wedbush Is Raising Aravive, Inc. (ARAV) Q4 19 Estimate To -0.42 From -0.57
5/10/2019 6:48:26 AM
Wedbush Is Increasing Aravive, Inc. (ARAV) Q3 19 Estimate To -0.53 From -0.72
5/10/2019 6:48:10 AM
Wedbush Is Raising Aravive, Inc. (ARAV) Q2 19 Estimate To -0.53 From -0.71
5/10/2019 6:47:24 AM
Wedbush Reiterates Aravive, Inc. (ARAV) At Outperform With $14 Price Target